Who are glycopyrronium Topical Wipes's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tiotropium bromide inhalation powder HandiHaler, Tiotropium & olodaterol, Trimbow pMDI, FF/UMEC/VI, LABA/LAMA or Placebo inhalation, TIO/OLO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glycopyrronium-topical-wipes.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

glycopyrronium Topical Wipes — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

glycopyrronium Topical Wipes (glycopyrronium Topical Wipes) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent / Antiperspirant. Area: Dermatology.

phase 3 Anticholinergic agent / Antiperspirant Muscarinic M3 receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

glycopyrronium Topical Wipes (glycopyrronium Topical Wipes) — Journey Medical Corporation. Glycopyrronium is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce sweat gland secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
glycopyrronium Topical Wipes TARGET	glycopyrronium Topical Wipes	Journey Medical Corporation	phase 3	Anticholinergic agent / Antiperspirant	Muscarinic M3 receptor
tiotropium bromide inhalation powder HandiHaler	tiotropium bromide inhalation powder HandiHaler	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist (LAMA)	Muscarinic M3 receptor
Tiotropium & olodaterol	Tiotropium & olodaterol	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
Trimbow pMDI	Trimbow pMDI	Medicines Evaluation Unit Ltd	marketed	Triple combination inhaler (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
FF/UMEC/VI	FF/UMEC/VI	Dr. Grace Parraga	marketed	Triple combination inhaler (ICS/LAMA/LABA)	Beta-2 adrenergic receptor, muscarinic M3 receptor, glucocorticoid receptor
LABA/LAMA or Placebo inhalation	LABA/LAMA or Placebo inhalation	Shanghai Pulmonary Hospital, Shanghai, China	marketed	LABA/LAMA combination bronchodilator	Beta-2 adrenergic receptor and muscarinic M3 receptor
TIO/OLO	TIO/OLO	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor and beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent / Antiperspirant class)

Journey Medical Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). glycopyrronium Topical Wipes — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-topical-wipes. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab